December 8, 2023
The goal should be improved metabolic function, better body composition, and a lower-risk physiologic state
When used in patients experiencing lower GI symptoms while taking GLP-1 medications, ARM allows clinicians to: Differentiate between drug-related motility effects and true pelvic floor dysfunction Quantify the severity of anorectal dysfunction to support diagnosis and treatment planning Establish a baseline prior to initiating biofeedback or behavioral therapy Monitor progress if conservative management is pursued Persistent Constipation in GLP-1 Users ARM can determine if dyssynergic defecation is contributing to delayed evacuation, guiding appropriate therapy beyond simply adjusting medication
If it stays small and improves within a day or two, it is often part of the same short-lived reaction pattern as mild redness or stinging
Supnet C, Bezprozvanny I
DECLARATIONS Authors contributions Performed literature search, review writing, data analysis, and interpretation: Ding M Made significant contributions to the conception, design, and revision of the manuscript: Luo Y Proposed the rationale and framework of review, provided guidance for manuscript design: Ji L Availability of data and materials Not applicable
